0 0 M o n t h 2 0 1 7 | V o L 0 0 0 | n A t U R E | 1 LEttER Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) affect 150 million people annually 1,2 . Despite effective antibiotic therapy, 30-50% of patients experience recurrent UTIs 1 .
In a mouse model, type 1 pilus-mediated binding to mannosylated receptors is indispensable for bladder colonization and invasion of urothelial cells lining the bladder lumen 2, 5 . Once inside urothelial cells, a single bacterium rapidly divides, forming an intracellular bacterial community (IBC) 2, 5 . Furthermore, UPEC can access underlying transitional cells, forming quiescent intracellular reservoirs 2, 5 . Mutations in fimH abolish the ability of UPEC to colonize the bladder, form IBCs and quiescent intracellular reservoirs 2, 5, 9 . By contrast, no role was observed for F17-like pili in the rate or severity of bladder infection after individual or concurrent transurethral inoculations of UTI89 and UTI89Δ ucl strains into the bladders of female C3H/HeN mice (Extended Data Fig. 3 ). Differences between mouse and human bladders or the overexpression of F17-like pili in vitro may account for the inconsistency with another study that showed a role for F17-like pili in binding to desquamated epithelial cells obtained from human urine 10 .
The fim and ucl operons encode two-domain tip adhesin proteins, FimH and UclD, respectively. The adhesin lectin domain contains the ligand-binding site, and the pilin domain joins the adhesin to the pilus rod 5 . Purified FimH lectin domain (FimH LD ) bound to more differentiated epithelial cells located in the upper portion of crypts and in 'surface epithelial cuffs' (the colonic homologues of small intestinal villi) ( Fig. 1l ). FimH binding was prevented by pretreating tissue sections with peptide-N-glycosidase F (PNGase F), which cleaves N-linked oligosaccharides. FimH LD also bound to Caco-2 cells (an immortalized human enterocyte-like cell line derived from colorectal carcinoma); binding was inhibited by d-mannose and a high-affinity mannose analogue (mannoside), M4284 (Extended Data Fig. 2b) 11 . The UclD lectin domain (UclD LD ) also bound colonic epithelial cells in tissue sections; binding was inhibited by pretreating tissue sections with O-glycosidase, an enzyme that cleaves O-linked oligosaccharides, suggesting that the UclD ligand is contained within an O-glycan (Fig. 1m ).
CUP pili are highly conserved throughout Proteobacteria and are assembled by dedicated chaperone-usher assembly machines encoded by each respective CUP operon along with the various subunit types comprising the pilus fibre 5, 7 . The sequence identity between usher genes of distinct CUP pilus types is greater than the identity of genes that encode other CUP pilus proteins and thus can be compared to determine evolutionary relationships of CUP pili among Proteobacteria 7, 12 . A homology search of a database of γ -Proteobacteria genomes revealed that the UTI89 F17-like usher gene sequence (uclC) shared highest identity with other E. coli uclC sequences and with orthologous usher sequences of Proteus mirabilis, a bacterium that can colonize the gut, and
Letter reSeArCH
Salmonella enterica, an intestinal pathogen (Supplementary Table 1 ). The uclC usher gene was also closely related to usher genes in F17 (thus the derivation of the name, F17-like), pVir99 and ECs1278 pili. A phylogenetic analysis showed clustering of these E. coli and Proteus species ushers into a distinct sub-branch within the broader F17 group usher phylogeny, suggesting that they share a common ancestor (Extended Data Fig. 4 ). F17-like pili are present in only 10% of E. coli strains; these strains are almost exclusively in the B2 clade, which contains most extraintestinal pathogenic E. coli (ExPEC) and UPEC *P < 0.05, **P < 0.01, ***P < 0.001 by Wilcoxon signed-ranked (a-j) or Mann-Whitney U test (k, n). n = 5 mice, 1 replicate (a, d-g); n = 10 mice, 2 replicates (b, h); n = 6 mice, 1 replicate (c); n = 14 mice, 3 replicates (i); n = 8 mice, 2 replicates (j); n = 12 mice, 3 replicates (UTI89); n = 9 mice, 2 replicates (UTI89Δfim); n = 15 mice, 3 replicates (UTI89Δucl); n = 10 mice, 2 replicates (UTI89ΔfimΔucl) (k). Replicates are biological (a-k). n = 3 tissue sections, 4 representative images per section (l, m). n = 3 wells, 3 technical replicates (n). 
Letter reSeArCH strains 10, 13 . By contrast, F17 and ECs1278 pili are found in the intestinal pathogens, enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC), respectively, which are specific to clades A, E and B1 (refs 14, 15) . These findings suggest that UPEC strains in clade B2 may have acquired the ucl operon from a different species and retained this factor to facilitate its residency in the gut. No binding of UclD LD was observed to N-acetylglucosamine (GlcNAc), the ligand bound by F17 pili, indicating that F17-like pili bind a distinct ligand from that of F17 pili 16 (Fig. 1n ). Notably, although the amino acid sequence of the full-length UclD adhesin has diverged from that of the F17 adhesin F17G, it is almost invariant across all strains encoding it (more than 99%), suggesting that there is a single, distinct ligand for UclD adhesins 10 .
A comparative genomic analysis of 43 strains isolated from a cohort of 14 women at the time of initial presentation with acute UTI, or during subsequent recurrent UTIs, revealed that 14 of the recurrent UTI events were caused by B2 strains 17, 18 (Supplementary Table 2 ). Of these 14 strains, 13 encoded F17-like pili (approximately 93%) (Extended Data Fig. 5 ). By contrast, F17-like pili have been found in less than 50% of all B2 strains 10 (E. coli reference collection; ECOR), suggesting that F17-like pili might be associated with UPEC persistence in women with recurrent UTI owing to their ability to promote maintenance of a UPEC intestinal reservoir.
To further characterize F17-like pili, we solved two X-ray crystal structures of UclD LD . The structures in the P2 1 (green) and P2 1 2 1 2 1 (grey) space groups were resolved to 1.05 Å and 1.60 Å resolution, respectively, and are nearly identical ( Fig. 2a (left); Supplementary Table 3 ). Despite low primary sequence identity (~ 25%), the structural characteristics of UclD LD and the F17 adhesin F17G LD are conserved 16 ( Fig. 2a-c) . This includes the presence of a transverse putative binding site in UclD LD located at a similar position to the GlcNAc-binding site on F17G ( Fig. 2a (right) , b, c) 16 . Structural and sequence alignments . EC 90 , 90% effective concentration to inhibit haemagglutination in vitro. b, C3H/HeN mice were intestinally colonized with UTI89 and given three oral doses of M4284 (100 mg kg −1 ), vehicle alone (10% cyclodextrin, control), or d-mannose (100 mg kg −1 ). c, d, UTI89 levels in the faeces and intestinal segments. e, UTI89 was introduced into the gut of C3H/HeN mice by oral gavage and into the bladder by transurethral inoculation before receiving three doses of M4284. Cm, chloramphenicol; Kn, kanamycin. f, g, UTI89 levels in the gut and urinary tract were assessed. Error bars represent median (a), geometric mean ± s.d. (c, d, f); and geometric mean (g). * P < 0.05, * * P < 0.01 by Mann-Whitney U test. n = 3 mice, 1 replicate (a); n = 14 mice (control); n = 15 mice (M4284); 3 replicates (c); n = 10 mice, 2 replicates (d); n = 9 mice, 2 replicates (f, g). All replicates are biological (a-g).
reveal two large conserved insertions in UclD relative to F17G ( Fig. 2c ), whose direct proximity to the putative binding pocket suggests that they are involved in UclD receptor binding. The six conserved residues that make up the candidate binding pocket in UclD are chemically distinct from their F17G counterparts (Fig. 2b, c) , providing further evidence that UclD binds a distinct ligand.
In light of the role of FimH and UclD in gut colonization, we conducted a study designed to reduce the UPEC intestinal reservoir with an adhesin-directed therapeutic. M4284 is a high-affinity biphenyl mannoside whose binding affinity for FimH is approximately 100,000fold higher than the natural sugar d-mannose 11, 19 . Pharmacokinetic analysis revealed that M4284 concentrations remain high in the faeces of mice for up to 8 h after an oral dose ( Fig. 3a ). Treating mice that were colonized by UTI89 with three doses (administered by oral gavage) of M4284, a regimen that successfully treats UPEC UTI in mice 20 , significantly reduced levels of UTI89 in the faeces, caecum and colon compared to those treated with a vehicle control (Fig. 3b, c ). Treating mice with additional M4284 doses further reduced the UTI89 population, and the overall number of UPEC continued to be lower in M4284-treated mice after termination of treatment (Extended Data Fig. 6 ). While d-mannose blocks FimH binding in vitro, treating mice with d-mannose did not alter UTI89 levels in vivo (Extended Data Fig. 2b, Fig. 3d ).
The infectious dose required to cause cystitis in 50% of mice (ID 50 ) in the UTI mouse model is 10 5 colony-forming units (CFU) 21 . Furthermore, decreasing the dose of UPEC introduced into the bladder from 10 8 to 10 6 CFU significantly reduced the rate of UTI, suggesting that the 1-1.5 log (or 90 -95%) mannoside-driven reduction in faecal UPEC levels would reduce the numbers of bacteria available to access the urinary tract and probably reduce the rate of UTI and/or recurrent UTI (Extended Data Fig. 7 ). Indeed, we found that M4284 simultaneously reduces UTI89 levels in the gut and urinary tracts of mice that were concurrently colonized with UTI89 in the gut and bladder ( Fig. 3e-g) .
We sequenced bacterial 16S rRNA gene amplicons generated from faecal samples of C3H/HeN mice that had not been given streptomycin or infected with UPEC but were treated with three doses of M4284 or vehicle alone. We found that M4284 produced no significant changes in the overall phylogenetic configuration of the microbiota as judged by the unweighted UniFrac dissimilarity metric, in contrast to the significant perturbations produced by treatment with ciprofloxacin, a fluoroquinolone antibiotic ( Fig. 4a , Extended Data Fig. 8a ). Using this UniFrac metric, we found that M4284 treatment did not produce significant perturbations in bacterial community structure in mice pretreated with streptomycin and then colonized with UTI89 (Extended Data Fig. 9 ). We concluded that M4284 can function to selectively extirpate UPEC from the gut in our preclinical model. Notably, although most Enterobacteriaceae carry the fim operon 7, 18, 22 , M4284 treatment does not significantly affect the abundance of intestinal Enterobacteriaceae (Extended Data Fig. 8a, b ), suggesting that these bacteria may not be expressing type 24) ), reduced the levels of each UPEC strain by a similar percentage in the faeces, caecum and colon ( Fig. 4b-f , Extended Data Fig. 10a ). Furthermore, we found that M4284 treatment reduced UTI89 levels in C3H/HeN and C57BL/6 mice from different vendors, containing distinct gut microbial communities. In each case tested, the percentage reduction in UPEC levels in caecum, colon and faeces did not vary significantly between the different treatment groups (Fig. 4f-h, Extended Data Figs 8c, 10b ). We concluded that M4284 treatment has activity against different UPEC strains in different host genetic backgrounds and gut microbial community contexts.
As the prevalence of antibiotic-resistant pathogens continues to rise, the need to develop highly targeted/specific therapeutic approaches has gained increased urgency 25, 26 . Furthermore, an increasing number of studies are finding that disruption of the gut microbiota by orally administered antibiotics, especially during childhood, may affect its functional properties in ways that are deleterious to the host, not only in the short term but also for more protracted periods of time 27, 28 . Therefore, developing therapeutic agents, such as mannosides, that specifically target a pathogen without disrupting the remainder of a microbial community has important ramifications not only for UPEC but also potentially for other infections, including those caused by enteropathogens. In addition, the identification of genes involved in UPEC intestinal colonization may provide a method by which patients with UTIs could be stratified for epidemiological studies of risk for recurrent disease as well as for proof-of-concept clinical studies of the efficacy of CUP-directed treatment regimens.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
MethOdS Ethics statement. The Washington University Animal Studies Committee approved all procedures used for the mouse experiments described in the present study. Overall care of the animals was consistent with The Guide for the Care and Use of Laboratory Animals from the National Research Council and the USDA Animal Care Resource Guide. For collection of colonic tissues for adhesion binding studies, mice were euthanized according to institutional, national and European animal regulations, using protocols that were also approved by the animal ethics committee of Ghent University. Bacterial strains. CUP operon and adhesin deletions in UTI89 were engineered by replacing the gene(s) of interest with antibiotic-resistance markers using the λ Red Recombinase system 29 . Earlier reports described wild-type UTI89 and its isogenic fim and fimH mutants 9,21 as well as EC958 (ref. 23), 41.4p (ref. 18 ) and CFT073 (ref. 24) . Colonization of mice with UPEC strains. Six-week-old female C3H/HeN mice were obtained from Envigo or Charles River Laboratories (CRL). Six-week-old female C57BL/6 mice were also obtained from Envigo. Animals were maintained in a single room in our vivarium for no more than 2 days before treatment. Before and after treatment all animals received PicoLab Rodent Diet 20 (Purina) ad libitum. All animals were maintained under a strict light cycle (lights on at 06:00, off at 18:00). For competitive infections, if a phenotype was observed after testing five mice (1 biological replicate), the experiment was repeated 1-2 times (total of n = 10-16 mice, 2-3 biological replicates). For 16S rRNA analyses, 4 -5 mice were examined (1 biological replicate). For all other experiments, 9 -16 mice were tested and the experiment was repeated 2-3 times (2-3 biological replicates). Exclusion criteria for mice were preestablished; (i) both introduced strains in competitive infections became undetectable during the course of a 14-day experiment, and (ii) mice died or lost more than 20% of their body weight. No mice in this study met these criteria. Mice were acquired from indicated vendors and randomly placed into cages (n = 5 mice per cage) by employees of Washington University's Division of Comparative Medicine; no additional methods for randomization were used to determine how animals were allocated to experimental groups. Investigators were not blinded to group allocation during experiments.
Animals received a single dose of streptomycin (1,000 mg kg −1 in 100 μ l water by oral gavage) followed 24 h later by an oral gavage of approximately 10 8 CFU UPEC in 100 μ l PBS. Bladder infections were performed via transurethral inoculation 30 . UPEC strains were prepared for inoculation as described previously 30 . In brief, a single UTI89 colony was inoculated in 20 ml of Luria Broth (LB) and incubated at 37 °C under static conditions for 24 h. Bacteria were then diluted (1:1,000) into fresh LB and incubated at 37 °C under static conditions for 18-24 h. Bacteria were subsequently washed three times with PBS and then concentrated to approximately 1 × 10 8 CFU per 100 μ l for intestinal infections and 1 × 10 8 CFU per 50 μ l for bladder infections.
In all cases, faecal and urine samples were collected directly from each animal at the indicated time points. Faecal samples were immediately weighed and homogenized in 1 ml PBS. Urine samples were immediately diluted 1:10 before plating. Mice were euthanized via cervical dislocation under isofluorane anaesthesia and their organs were removed and processed under aseptic conditions. Intestinal segments (caecum and colon) were weighed before homogenization and plating on LB supplemented with the appropriate antibiotic. Enumeration of bladder intracellular bacterial communities. Six-week-old C3H/HeN mice were given a single oral dose of either M4284 (100 mg kg −1 ) or vehicle control (10% cyclodextrin) 30 min before transurethral inoculation with UTI89. To count accurately the number of IBCs, mice were euthanized 6 h after infection. Bladders were removed aseptically, bisected, splayed on silicone plates and fixed in 4% (v/v) paraformaldehyde. IBCs, readily discernable as punctate violet spots, were quantified by LacZ staining of bladder wholemounts 20, 31 . Immunofluorescence studies. The protocols used for immunohistochemical analysis are based on a previous study 32 . After euthanization of 6-week-old, female C57BL/6 mice (supplied by VIB-Ghent University breeding program, Belgium), segments of colon were fixed in methanol-Carnoy for a minimum of 3 h at room temperature. The fixed tissues were then embedded in paraffin and 4-μ m-thick sections were cut and placed on glass slides. Slides were de-paraffinized and rehydrated by incubating them in xylene, isopropanol, 100% ethanol and finally 70% ethanol (each step involving a 3 min incubation in the reagent followed by another 3 min incubation in fresh reagent). Slides were subsequently rinsed in tap water and PBS, placed in blocking buffer (5% fetal calf serum prepared in PBS) at room temperature for 30 min, and then incubated with rabbit polyclonal antibodies to Muc2 (1:2,000; mucin 2 (H-300), Santa Cruz Biotechnology) for 2 h. After three washes with PBS, slides were incubated with a goat anti-rabbit Dylight-488 labelled secondary antibody (1:1,000 dilution, ThermoFisher 35553) in blocking buffer for 1 h at room temperature. Slides were washed three times with PBS before counterstaining with bis-benzimide (Hoechst dye) (1:1,000 in PBS) for 10 min at room temperature. Finally, slides were incubated with FimH LD or UclD LD (P2 1 ) protein, labelled with NHS 650 nm Dylight, in blocking buffer at 4 °C overnight.
Before staining, sections were treated with O-glycosidase (NEB) or PNGase F (Sigma) at 37 °C using buffers and protocols supplied by the manufacturer. Slides were washed subsequently with PBS before treatment with fluoro-mounting medium (n-propyl gallate in glycerol) and viewing under a confocal microscope (Leica Microsystems LAS-AF-TCS SP5) using a 20 × 125 objective. Mannoside treatment. d-mannose or the mannoside M4284 (which has been characterized in a previous study 11 ), were diluted in vehicle (water and 10% cyclodextrin, respectively) and administered to 6-week-old C3H/HeN mice at a dose of 100 mg kg −1 . Control animals were treated with water or 10% cyclodextrin alone. Unless stated otherwise, three doses of M4284, cyclodextrin, or d-mannose were given via oral gavage over 24 h, with doses administered 8 h apart. Mice were euthanized and intestinal tissues were processed for analysis of viable bacteria (CFU) 8 h after the last dose, unless otherwise noted. To test the effect of M4284 on intestinal UPEC titres after treatment was terminated, mice were euthanized 5 days after the last dose of mannoside. To test the effect of additional doses on M4284 treatment on UPEC titres, mice were given five doses of mannoside; the first three doses were administered 8 h apart, followed 12 h later by the fourth dose, and 24 h later by the fifth dose. Mice were euthanized 24 h after the fifth dose. Carriage of F17-like pili. We examined 43 available UPEC isolates (Supplementary Table 2 ). These isolates originated from a clinical study of 14 women who experienced at least two episodes of a UTI (an initial UTI and one or more recurrent UTIs) during the 90-day study window 17 . The isolates used in this work were sequenced in a previous study 18 (Bioproject ID PRJNA269984) and include (i) 14 isolates collected at enrollment, (ii) 18 isolates collected during recurrent UTI (10 women experienced a single recurrent UTI while four women experienced two recurrent UTI events), and (iii) 11 isolates collected in the days leading up to a recurrent UTI.
The distribution of the F17-like operon in these clinical E. coli isolates was determined using BLAST and the F17-like operon from UTI89 as the query sequence. A 'hit' was considered as any genome sequence that matched the entire length of the query sequence with more than 75% identity. As a control to prevent false negatives in the BLAST search of draft genomes, DNA sequencing reads from each clinical UPEC isolate were mapped against a reference sequence constructed by concatenating all the ucl genes with 100 N-separators using Geneious v6.1.7 (ref. 33) . Phylogenetic analyses and sequence alignments. Amino acid alignments of fulllength UTI89 UclD, P. mirabilis UcaD, S. enterica UclH, and ETEC F17G were conducted using the MAFFT L-INS-i iterative refinement method and the default BLOSUM62 scoring matrix 34 ( Supplementary Table 1 ). MAFFT collected up to 100 homologues with E values of less than 1 × 10 −10 to each sequence from the SwissProt database to improve alignment accuracy. Homologues are automatically removed from the final alignment. The alignment was visualized using Geneious 33 . A homology search of the coding sequence database of the European Nucleotide Archive (ENA) was conducted using the Basic Local Alignment Search Tool (BLAST) 35 using the UTI89 uclC (ENA accession ABE10308) and EDL933 ECs1278 (ENA accession AIG67653) as queries. Sequences that matched either gene sequence with more than 50% identity were downloaded and then filtered to remove partial hits (less than 80% length of query sequence) and sequences with nonsense mutations, which resulted in a total of 659 sequences ( Supplementary Table 1 ). Duplicate sequences were then removed, resulting in a list of 122 unique, representative sequences. These sequences were then aligned with the UTI89 fimD usher sequence (ENA accession ABE10417) as an outgroup using the MAFFT MAFFT L-INS-i alignment method and the 200PAM scoring matrix 34 : The phylogenetic relationship between gene sequences was then estimated using RAxML v8.1.3 with the GTRCAT model and supported with 1000 bootstrap replicates; the tree was visualized using the tool interactive Tree of Life (iTOL) v3 (ref. 36) . ELISA targeting FimH. Caco-2 cells (ATCC number HTB-37) were cultured in minimum essential medium (MEM) supplemented with 20% FBS. Cell cultures tested negative for mycoplasma. Cells were split into 48-well plates, grown to 100% confluence and then fixed with paraformeldahyde for 15 min followed by treatment with blocking buffer (PBS containing 2% BSA) for 2 h. A truncated FimH, corresponding to residues 1-178 of the mature FimH adhesin (FimH LD ), expressed in E. coli and purified as described previously 37 , was serially diluted in blocking buffer and incubated with the fixed Caco-2 cells for 1h at room temperature. To test the effect of d-mannose or M4284 on FimH binding, 0.2 mg ml −1 FimH LD was pre-incubated for 5 min in the presence or absence of 1 mM d-mannose (Sigma-Aldrich) or 1 mM M4828 (in 20 mM Tris, pH 8.0, or 20 mM Tris plus water or 10% cyclodextrin, respectively) before serial dilution and incubation. Wells were washed four times with PBS and 0.05% Tween 20 (PBST) before incubation with a polyclonal rabbit anti-T3 antibody against FimH LD (generated against FimH residues 1-165; ref. 37) for 1 h at room temperature. After another series of four washes, secondary antibody (goat anti-rabbit Ig conjugated to horseradish peroxidase; ThermoFisher, 32460) was incubated with the cells for 1 h at room temperature (24 °C) before washing in PBST. Plates were developed with the BD OptEIA TMB substrate reagent kit for 5 min at room temperature (24 °C) before quenching with transferred to a solution containing 0.1 M potassium phosphate (monobasic), 0.2 M potassium iodide and 20% PEG 3350 supplemented with 20% glycerol before being flash-frozen in a bath of liquid nitrogen. Data were collected at beamline 4.2.2 (ALS Berkeley) to 1.6 Å resolution. Data were indexed and processed with XDS 42 , scaled and merged AIMLESS in the CCP4 suite 43 and phased with the Single anomalous dispersion (SAD) method using phenix.autosol, and refined with phenix.refine 44 . Data and refinement statistics can be found in Supplementary Table 3 . r.m.s.d. values were calculating using the DALI server 45 . Structural alignments were performed in PROMALS3D using the default settings. Secondary structure assignments for UclD LD were completed using DSSP. Differential scanning fluorimetry. Purified UclD LD (1.4 μ g per well) was incubated with 5× Sypro orange fluorescent dye in 20 mM Tris, pH 8.0, with or without 10 mM monosaccharide in a total volume of 70 μ l. Samples were heated from 20 °C to 100 °C in 30-s/0.5 °C increments using a Bio-Rad C1000 thermocycler with CFX96 RT-PCR attachment. The reported melting temperatures were determined by the inflection point of the sigmoidal graph. Data availability. Bacterial V4-16S rRNA data sets have been deposited in the European Nucleotide Archive (ENA) under accession number PRJEB19121. Sequences used to examine the carriage of F17-like pili in clinical recurrent UTI isolates were previously published 18 and are deposited in the NCBI under the BioProject accession PRJNA269984. Crystallography data have been deposited in the Protein Data Bank (PDB) under accession codes 5NWP (P2 1 ) and 5VQ5 (P2 1 2 1 2 1 ). All other data are available from the corresponding author upon reasonable request. Code availability. No new code was generated for this study. All software was obtained from publicly available sources; papers describing the software are cited in the text. Statistical analysis. No statistical methods were used to predetermine sample size. The statistical significance of differences between groups in experiments (excluding competitive infections) was determined by a Mann-Whitney U test. The competitive index was defined as: (CFU output strain A/CFU output strain B)/(CFU input strain A/CFU input strain B). For competitive infections, statistical significance was determined by a Wilcoxon signed-rank test. Statistical analyses were performed using Graphpad Prism 7.
1 M H 2 SO 4 . Binding was assessed by measuring the absorbance at 450 nM on a TECAN infinite 2 PRO plate reader. Wells lacking protein were used as control. All conditions were examined in quadruplicate. Effect of antibiotic exposure on the microbiota. Six-week-old female C3H/HeN mice from Envigo and CRL were subjected to the following treatments: (i) none (naive control mice, untreated), (ii) three doses of M4284 (100 mg kg −1 ; in 10% cyclodextrin) or 10% cyclodextrin given 8 h apart, or (iii) ciprofloxacin (two doses of 15 mg kg −1 given 12 h apart). All doses were given via oral gavage. Five mice were included for each treatment type (1 biological replicate) and faecal samples were collected before treatment and 24 h after the last dose of each treatment. Another group of four C3H/HeN mice from Envigo (1 biological replicate) were pretreated with streptomycin and colonized with UTI89 before receiving treatment with either three doses of M4284 (100 mg kg −1 ; in 10% cyclodextrin) or with 10% cyclodextrin alone; faecal samples were collected before treatment but after exposure to streptomycin and UTI89 and 24 h after the last dose of each treatment. Bacterial 16S rRNA sequencing. DNA was extracted by bead beating in extraction buffer (200 mM Tris, pH 8.0, 200 mM NaCl, 20 mM EDTA), 210 μ l of 20% SDS and 500 μ l phenol:chloroform:isoamyl alcohol (pH 7.9, 25:24:1). This crude DNA extract was purified (Qiaquick PCR purification kit) and PCR used to generate amplicons from the V4 region of bacterial 16S rRNA genes using primers and cycling conditions described previously 38 . Amplicons were pooled in equimolar ratios and sequenced on an Illumina MiSeq instrument (paired-end 250-nucleotide reads). Paired V4-16S rRNA sequences were merged using FLASH software 39 , demultiplexed, and reads clustered into 97%ID OTUs (2013 Greengenes OTU reference database; QIIME version 1.9.0; ref. 40) . A custom database using modified NCBI bacterial taxonomy was used to train the Ribosomal Database Project (RDP) version 2.4 classifier and assign taxonomy to picked OTUs 41 . The resulting OTU table was filtered to include only OTUs found in at least two samples at greater than or equal to 0.1% relative abundance. F17-like constructs and purification. For the P2 1 UclD LD construct, the first 197 amino acids of the mature UclD adhesin protein were cloned into pDEST14 using Gateway technology (Invitrogen), resulting in plasmid pUclD AD . Expression was induced with 1 mM IPTG. Periplasmic extracts were prepared by resuspending bacterial pellets in 20 mM Tris, 20% sucrose, pH 8 (4 ml per gram of pellet). Subsequently, 40 μ l of 0.5M EDTA and 10 mg ml −1 lysozyme were added per gram of pellet and the suspension was incubated on ice for 30 min. This step was followed by addition of 40 μ l of 2.5 M MgCl 2 per gram of cell pellet and incubation on ice for 5 min. Cells were spun at 15,000g and the supernatant was saved as the periplasmic extract. The extract containing the UclD lectin domain was dialysed against 20 mM HEPES, pH 7, passed over a SP FF cation exchange column (GE Healthcare) and bound material eluted with 20 mM HEPES, pH 7, 1 M NaCl. Pooled fractions containing UclD lectin domain were then applied to a Phenyl Hi Trap column (GE Healthcare) after addition of 1 M ammonium sulfate. Elution was performed using 20 mM HEPES, pH 7.
To generate purified UclD LD for the P2 1 2 1 2 1 space group, DNA from the UTI89 uclD gene encoding the N-terminal 217 amino acids of the protein were cloned into pTRC99a with a C-terminal 6-His tag. This construct was expressed in the periplasm of E. coli DL41(DE3), a methionine auxotroph strain suitable for expression of native or selenomethionine-labelled protein. Periplasmic extracts were first dialysed against PBS supplemented with 250 mM NaCl, then bound to a cobalt (Goldbio) column; bound proteins were eluted with PBS containing 250 mM NaCl, and 250 mM imidazole. Pooled fractions were dialysed into 20 mM MES, pH 5.8, bound to an HR16/10 Mono S cation exchange column (GE Healthcare), and eluted with 300 mM NaCl. After cleavage of the periplasmic localization sequence, the mature form of UclD LD -6× His contained 203 amino acids.
Selenomethionine-labelled protein was purified using the same protocol, but all buffers were supplemented with 2 mM β -mercaptoethanol and 1 mM EDTA to prevent oxidation. EDTA was omitted from the periplasmic dialysis buffer to prevent chelation of immobilized cobalt. Crystallization and structure determination. For the P2 1 UclD LD structure solved in the P2 1 space group, UclD LD (15 mg ml −1 ) was crystallized using sitting drop vapour diffusion against a solution containing 16% PEG 4000, 0.1 M Tris-HCl, pH 8.5, 0.2 M magnesium chloride. UclD crystals were flash cooled to 100 K in a solution containing 16% PEG 4000, 0.1 M Tris-HCl, pH 8.5, 0.2 M magnesium chloride and 30% glycerol. Data were collected at beamline ID29 (ESRF, Grenoble, France) to 1.05 Å resolution. Data were indexed and processed with XDS 42 , scaled and merged using SCALA in the CCP4 suite 43 . Data and refinement statistics can be found in Supplementary Table 3 .
For the UclD LD structure solved in the P2 1 2 1 2 1 space group, UclD LD (10 mg ml −1 10 mM MES pH 5.8) was crystallized by the hanging drop vapour diffusion method against a well solution containing 0.1 M potassium phosphate (monobasic), 0.2 M potassium iodide and 20% PEG 3350. One microlitre of the protein solution was mixed with 1 μ l well solution and incubated at 18 °C. Crystals were harvested and Letter reSeArCH Extended Data Figure 1 | Streptomycin treatment allows for persistent UTI89 colonization of the caecum and colon in female C3H/HeN and C57BL/6 mice. a, Mice were pretreated with streptomycin and subsequently colonized via oral gavage (PO) with UTI89, a prototypical human UPEC cystitis isolate. b-e, Colonization of UTI89 in C3H/HeN (b, c) or C57BL/6 (d, e) mice from Envigo was assessed by quantifying CFU in faecal samples collected over the course of 21 days from mice who did not receive streptomycin (white circles) or mice pretreated with the antibiotic (black circles). CFU analysis of levels of colonization in the caecum and colon were defined by analysing tissue homogenates prepared 21 days after colonization. Symbols represent geometric mean ± s.d. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001 by Mann-Whitney U test. n = 15 mice, 3 biological replicates (b-e).
Extended Data Figure 5 | Phylogenetic distribution of F17-like carriage in UPEC from patients with recurrent UTI. The phylogeny of a set of clinical UPEC strains (n = 43 with taxon labels highlighted in green, orange or grey) was contextualized with reference E. coli strains (n = 46, unhighlighted taxon labels) by comparing the concatenated single-copy, core genes of the strains using the RAxML algorithm and the GTRCAT model 46 . Highlighted taxon labels indicate UPEC isolates collected at enrolment (green) and during recurrent UTI (orange). In all cases, patients cleared each infection before recurrence, no patient exhibited signs of asymptomatic bacteriuria. The study design also allowed for the collection, from cohort participants, of E. coli isolates present in the urine in the days leading up to their clinical visit and recurrent UTI diagnosis (highlighted in grey) 17 . Branch lines indicate phylogenetic background for strains from clade B2 (red branch lines) and non-B2 clades (blue branch lines). Carriage of F17-like pili (black stars) was limited to the B2 clade and enriched within recurrent UTI UPEC isolates. Bootstrap supports are indicated at internal nodes. Bootstrap values greater than 95 have been removed. The clade to which each strain belongs is indicated in brackets to the right.
